Related references
Note: Only part of the references are listed.Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Shengli Xia et al.
LANCET INFECTIOUS DISEASES (2021)
Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine
Krishna Mohan Vadrevu et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Alba Grifoni et al.
CELL (2020)
The Challenges of Vaccine Development against a New Virus during a Pandemic
Michael S. Diamond et al.
CELL HOST & MICROBE (2020)
Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development
Kevin W. Graepel et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Rapid COVID-19 vaccine development
Barney S. Graham
SCIENCE (2020)
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Feng-Cai Zhu et al.
LANCET (2020)
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Bette Korber et al.
CELL (2020)
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials
Shengli Xia et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome
Daniela Weiskopf et al.
SCIENCE IMMUNOLOGY (2020)
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Feng-Cai Zhu et al.
LANCET (2020)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M. Folegatti et al.
LANCET (2020)
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J. Mulligan et al.
NATURE (2020)
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Ann M. Arvin et al.
NATURE (2020)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
E. J. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Genomic analysis of SARS-CoV-2 strains among Indians returning from Italy, Iran China, Italian tourists in India
Varsha Potdar et al.
INDIAN JOURNAL OF MEDICAL RESEARCH (2020)
First isolation of SARS-CoV-2 from clinical samples in India
Prasad Sarkale et al.
INDIAN JOURNAL OF MEDICAL RESEARCH (2020)
A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants
Raches Ella et al.
VACCINE (2019)
A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC (R), administered simultaneously with or without the buffering agent in healthy infants in India
Raches Ella et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Advances in aluminum hydroxide-based adjuvant research and its mechanism
Peng He et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life
Nita Bhandari et al.
VACCINE (2014)
Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways
Victoria J. Philbin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Potent Adjuvanticity of a Pure TLR7-Agonistic Imidazoquinoline Dendrimer
Nikunj M. Shukla et al.
PLOS ONE (2012)
Immunogenicity and safety study of Indirab: A Vero cell based chromatographically purified human rabies vaccine
Gadey Sampath et al.
VACCINE (2010)
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease
Maria Florencia Delgado et al.
NATURE MEDICINE (2009)
Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling
Felix Geeraedts et al.
PLOS PATHOGENS (2008)
Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection
TR Johnson et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2004)
Toll-like receptors control activation of adaptive immune responses
M Schnare et al.
NATURE IMMUNOLOGY (2001)
Share Paper
